Company Overview of ProtAffin Biotechnologie AG
ProtAffin Biotechnologie AG, a pre-clinical stage biotechnology company, develops protein-based biopharmaceutical products for chronic inflammatory diseases and oncology. It develops products based on CellJammer, a discovery technology for targeting protein-glycan interactions using modified human proteins. The company’s products include PA401, which is a modified form of the human chemokine IL-8 and acts as an anti-inflammatory protein preventing the infiltration of neutrophils in chronic respiratory diseases and acute inflammatory diseases. ProtAffin Biotechnologie AG was founded in 2005 and is based in Graz, Austria with an additional office in Vienna, Austria.
Founded in 2005
43 316 382 541
43 316 382 541 4
Key Executives for ProtAffin Biotechnologie AG
Similar Private Companies By Industry
|ARTMA Medical Technologies AG||Europe|
|CELL MED Research GmbH||Europe|
|Apeptico Forschung und Entwicklung GmbH||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact ProtAffin Biotechnologie AG, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.